5.960USD+2.59%Mkt Cap: 1.71B USDP/E: —Last update: 2026-06-01
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central ner…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.71B USD
Enterprise Value1.47B USD
Revenue (TTM)7.47M USD
Gross Profit7.47M USD
Net Income (TTM)-109.00M USD
Revenue/Share0.0220 USD
Last Price5.960 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees99
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.27
PEG—
EV/EBITDA-11.22
EV/Revenue197.36
P/S225.78
P/B6.78
EPS (TTM)-0.38
EPS (Forward)-0.44
52W Range
2.25073% of range7.300
52W High7.300 USD
52W Low2.250 USD
Profitability
Gross Margin100.00%
Oper. Margin-1774.37%
EBITDA Margin0.00%
Profit Margin-1115.27%
ROE-44.14%
ROA-31.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-93.09M USD
CapEx (TTM)738.00K USD
FCF Margin-983.11%
FCF Yield-4.28%
Net Debt-208.03M USD
Net Debt/EBITDA1.58
Balance Sheet
Debt/Equity0.28
Current Ratio14.04
Quick Ratio13.76
Book Value/Sh0.8660 USD
Cash/Share0.9620 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)12.23 USD
Target Range8.000 USD – 19.00 USD
# Analysts13
Ownership
Shares Out.287.36M
Float196.96M
Insiders10.62%
Institutions95.74%
Short Interest
Short Ratio12.3d
Short % Float13.00%
Short % Out.12.77%
Shares Short36.70M
Short (prev mo.)38.92M
Technical
SMA 505.582 (+6.8%)
SMA 2004.685 (+27.2%)
Beta1.23
S&P 52W Chg27.70%
Avg Vol (30d)2.18M
Avg Vol (10d)2.34M
Technical Indicators
RSI (14)48.4
MACD-0.0569
MACD Signal0.0254
MACD Hist.-0.0823
BB Upper7.368 USD
BB Middle6.158 USD
BB Lower4.948 USD
BB Width39.30%
ATR (14)0.3828 USD
Vol Ratio (20d)0.48x